STAT+: Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575 million, lowering hopes of a buyout
Cytokinetics, a drugmaker that is expected to soon launch a promising new heart therapy called aficamten, said Wednesday that it had agreed to pay biotech firm Royalty Pharma a higher royalty on the medicine in return for up to $575 million, which will be …